HACKENSACK, N.J., July 24, 2015
HACKENSACK, N.J., July 24, 2015 /PRNewswire/ -- Champions Oncology (OTC-BB: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year quarter ended April 30, 2015, on Tuesday, July 28, 2015, before market open.
The company will host a conference call to discuss the results that day at 9:00 a.m. EDT (6:00 a.m. PDT). To participate in the call, please call 800-875-3456 (domestic), 800-648-0973 (Canadian Toll Free) or 302-607-2001 (international) ten minutes ahead of the call and give the verbal passcode "Champions Oncology."
An MP3 recoding of the call will be available on the Investor tab of the company's website within 72 hours.
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company's technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune-deficient mice to create TumorGrafts that preserve the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. For more information, please visit www.championsoncology.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/champions-oncology-to-announce-fourth-quarter-financial-results-on-tuesday-july-28-300118191.html
SOURCE Champions Oncology, Inc.